170 related articles for article (PubMed ID: 7655134)
21. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
[TBL] [Abstract][Full Text] [Related]
22. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
[TBL] [Abstract][Full Text] [Related]
23. Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus.
Canada TW; Weavind LM; Augustin KM
Ann Pharmacother; 2003 Jan; 37(1):70-3. PubMed ID: 12503936
[TBL] [Abstract][Full Text] [Related]
24. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever.
Ellis M; Bernsen R; Ali-Zadeh H; Kristensen J; Hedström U; Poughias L; Bresnik M; Al-Essa A; A Stevens D
J Med Microbiol; 2009 Nov; 58(Pt 11):1474-1485. PubMed ID: 19589901
[TBL] [Abstract][Full Text] [Related]
25. Rapid intravenous infusion of amphotericin B: a pilot study.
Cruz JM; Peacock JE; Loomer L; Holder LW; Evans GW; Powell BL; Lyerly ES; Capizzi RL
Am J Med; 1992 Aug; 93(2):123-30. PubMed ID: 1497007
[TBL] [Abstract][Full Text] [Related]
26. Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever.
Spitzer TR; Creger RJ; Fox RM; Lazarus HM
Pharmatherapeutica; 1989; 5(5):305-11. PubMed ID: 2748690
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
28. Acute renal failure with amphotericin B in lipid emulsion.
Gales MA; Gales BJ; Alford KM
Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
[No Abstract] [Full Text] [Related]
29. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
30. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
31. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.
Ariano RE; Mitchelmore BR; Lagacé-Wiens PR; Zelenitsky SA
Ann Pharmacother; 2013 Jun; 47(6):e26. PubMed ID: 23673538
[TBL] [Abstract][Full Text] [Related]
33. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
34. Amphotericin B revisited: reassessment of toxicity.
Clements JS; Peacock JE
Am J Med; 1990 May; 88(5N):22N-27N. PubMed ID: 2368770
[TBL] [Abstract][Full Text] [Related]
35. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
36. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
37. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
Steimbach LM; Tonin FS; Virtuoso S; Borba HH; Sanches AC; Wiens A; Fernandez-Llimós F; Pontarolo R
Mycoses; 2017 Mar; 60(3):146-154. PubMed ID: 27878878
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
Singh GP; Saxena RK; Priyadarshy V
J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
[TBL] [Abstract][Full Text] [Related]
40. Respiratory distress secondary to both amphotericin B deoxycholate and lipid complex formulation.
Rolland WA; Guharoy R; Ramirez L; Blair D; Medicis J; Khan U
Vet Hum Toxicol; 2000 Aug; 42(4):222-3. PubMed ID: 10928687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
